drugset / Trial / NCT02251171

Effects of Steady-state TPV/RTV on the Single-dose Pharmacokinetics of Rifabutin and the Effects of Single-dose Rifabutin on the Steady-state Pharmacokinetics of TPV in Healthy Adult Volunteers

NCT02251171

Phase 1 Completed 24 enrolled Boehringer Ingelheim
NaSingle-groupOpen-labelTreatment

Summary

Study to determine the effects of steady-state Tipranavir (TPV) / Ritonavir (RTV) (500mg/200mg bid) on the single-dose pharmacokinetics of Rifabutin (RFB) and to determine the effects of single-dose RFB on the steady-state pharmacokinetics of TPV 500mg (co-administered with RTV 200mg)

Timeline

Start
2003-08
Primary completion
2003-10
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Rifabutin Small molecule 150 mg
Subject Tipranavir Small molecule 500 mg
Background Ritonavir Other / unclassified 200 mg

Indications

No indication recorded.